Intuitively, it seems evident that these DNA repairassociated genes (ATM, RB1, and FANCC) are related to the response to NAC. But DNA alterations do not necessarily reflect functional and structural changes of a given protein. To investigate the potential biological consequence of a given alteration, they used computed prediction models. Indeed the vast majority of alterations were predicted to be deleterious. However, only structural analysis of the proteins and the subsequent loss of their biological function may allow to prove the consequences of these genomic DNA alterations.
Recently two other groups investigated genomic DNA alterations of pretreatment tumor tissue and related their findings with likelihood of response to NAC (7, 11) . Van Allen et al. discovered that somatic mutations in ERCC2, a gene related to DNA-repair, were associated with favorable response (11) . Interestingly, they proved their findings in vitro and showed that ERCC2-deficient cell lines failed to rescue cisplatin sensitivity. Groenendijk et al. found that only complete responders but none of the nonresponders showed missense mutations in ERBB2 (7). The trend for more missense mutations in ERCC2 in complete responders was not significant. Interestingly, all groups identified different genomic DNA alterations. Several reasons could explain this inconsistency. The rather small cohorts (range, 24-71), differences in cohort enrolment and NAC regimens might influence the discovery. The clinical stages of these cohorts are comparable but there are differences in practice patterns. While NAC is considered in all patients with muscle-invasive bladder cancer in North America, this is less common in Europe where NAC is predominantly suggested for higher staged patients. Therefore, the rate of surgical downstaging may be different. Two studies reported a common finding (11, 12) . Responders had a significantly higher rate of somatic mutations when compared with non-responders. In general, bladder cancer as well as other cancers induced by carcinogens such as tobacco smoke shows a higher rate of somatic mutations (15, 16) . A somehow ironic consequence may be that smokers respond better to NAC than nonsmokers. Only Van Allen et al. provided smoking status but this data did not show a trend that supports this hypothesis (11) . However, this could be an interesting question for future studies investigating genomic DNA alterations in relation with response to NAC.
A definitive validation of these findings is still needed. Ideally, future cohorts should be larger, treated with a specific chemotherapy regimen, combined with a chemonaive cohort to define the biomarker as predictive rather than prognostic and include all genes of interest. Another open question is the appropriate study endpoint. The nature is rarely black or white and why should this be the case in response to NAC? I would suggest a three-graded system for example as follows: Complete, partial and non-responders. Patients without remaining tumor are obviously complete responders. Patients with urothelial in-situ carcinoma and non-invasive papillary tumors should also be categorized as complete responders. These tumors are rarely lethal, are not treated with cisplatin and have similar outcomes when compared with patients without residual tumors (17) . Patients with extravesical extension of the remaining primary tumor and lymph node metastasis should be categorized as non-responders. But how would we categorize patients with invasive organ confined residual tumors? Several studies showed similar outcomes of patients with organ confined residual tumors invading into the submucosa and muscle, respectively (4, 17, 18) . More importantly, patients with muscle-invasive organ confined disease had a significant better outcome than those with extravesical extension of residual tumors. Therefore, I would categorized those patients with invasive but organ confined residual tumors as partial responders. An advantage of the suggested three categories would be that surgical downstaging of nonresponders is very unlikely. We might also include other parameters, for example histological signs and regression in surgical specimens after NAC. Recently, we described these histological signs and suggested a tumor regression grade that categorizes response to NAC (19) . But these findings need to be validated in larger datasets before being taken into account for newly defined categories. In addition, we might also be able to identify biomarkers assessed in residual tumors that define response to NAC. Eventually, a combination of pathological staging, histological assessment and biomarkers might be used to define new categories. Of course, these suggested categories are pure speculation. But the fact is that all three studies (7, 11, 12) used different patient categories with regard to response to NAC. This indicates that its definition suggested in the literature is not generally accepted. Therefore, a valid definition of response to NAC will be essential for future biomarker studies.
